7 May 2020 - Subcutaneous rheumatoid arthritis treatment Remsima SC launched in the Netherlands, its third European market, Celltrion Healthcare said Thursday.

Remsima SC is an under-the-skin injection of infliximab biosimilar that treats auto-immune diseases. So far, it is approved to treat RA indication, and is still in the process of adding inflammatory bowel disease indication.

Celltrion Healthcare said it inked a partnership with the biggest Dutch private health insurance company CZ, who will return all Remsima SC costs for patients.

Read Korea Herald article